Osteoporosis: Clinical Trials

220 trials for Osteoporosis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

149 completed, 27 unknown, 13 recruiting, 10 active not recruiting. 220 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 4220Completed 149, Unknown 27, Recruiting 13, Active not recruiting 10, Terminated 8, Not yet recruiting 6, Withdrawn 6, Enrolling by invitation 1

Follow Osteoporosis: new trials by email Literature Review of Osteoporosis trials Research Report on Osteoporosis

Trials (filtered) newest first · largest first

All 220 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Sequential Treatment With Romosozumab Followed by Denosumab vs. Zoledronic Acid for Gains in HIP BMD
Romosozumab, Zoledronic Acid 5 MG in 5 ML Injection, Calcium 500 mg and Vitamin D3 800 IU - Osteoporosis in Post-menopausal Women
Phase 4Not yet recruitingSahlgrenska University Hospital2162027-01-112026-08-19
Romosozumab and Denosumab Combination Therapy for Osteoporosis
Romosozumab, Romosozumab and Denosumab - Postmenopausal Osteoporosis
Phase 4Not yet recruitingMassachusetts General Hospital1002027-01-012026-11-03
Romosozumab Versus Denosumab In Glucocorticoid-induced Osteoporosis: An Extended Observation Of a Clinical Trial at 6 Years
Romosozumab, Denosumab - Glucocorticoid-Associated Osteopenia and Osteoporosis
Phase 4Not yet recruitingTuen Mun Hospital542026-09-012026-08-12
The Comparison of Ibandronate and Zoledronic Acid After Denosumab Discontinuation
Ibandronate IV, Zoledronic acid IV - Postmenopausal Osteoporosis, Postmenopausal Osteopenia
Phase 4RecruitingNational Taiwan University Hospital522026-08-202026-08-25
Osteoporotic Fracture and Lidocaine Plaster 5% for Neuropathic Pain preventioN
Lidocaine 5% medicated plaster - Osteoporotic Vertebral Fracture, Neuropathic Pain
Phase 4Not yet recruitingUniversity Hospital, Clermont-Ferrand302026-07-012026-07-08
Step-down Therapy After Long-term Osteoporosis Treatment
zoledronate, Denosumab De-escalation - Osteoporosis
Phase 4RecruitingNational Taiwan University Hospital442026-01-012025-12-15
Romosozumab and Denosumab, Alone or Combined, in Postmenopausal Osteoporosis
Denosumab, Romosozumab - Osteoporosis
Phase 4RecruitingNational Taiwan University Hospital902025-12-032025-12-16
GLP-1R Actions on Muscle and the Skeleton
Tirzepatide, Lifestyle toolkit - Musculoskeletal Abnormalities, Obesity
Phase 4RecruitingPennington Biomedical Research Center502025-10-092026-08-27
StrAtegies For Zoledronic Acid Post-dEnosumab Discontinuation in Postmenopausal oSTeoporosis
a second infusion of ZOL when crosslaps levels reach 300 pg/mL, a rescue second infusion at month-12 (standard traitment) - Postmenopausal Osteoporosis
Phase 4RecruitingUniversity Hospital, Toulouse2002025-10-022025-12-31
The Effect of Semaglutide on Bone Health
semaglutide combined with metformin - Osteoporosis, Osteoporosis Fracture
Phase 4Not yet recruitingThe First Affiliated Hospital of Xiamen University1502025-09-152025-09-17
Effects of Cycle Therapy vs Sequential Therapy With Romosozumab and Denosumab in Postmenopausal Osteoporosis Patients
Romosozumab followed by Denosumab, Romosozumab and Denosumab Cycle Therapy - Osteoporosis, Osteoporosis Postmenopausal
Phase 4RecruitingNational Taiwan University Hospital702025-04-082026-06-23
A Clinical Study on the Effect of Discontinuing Alendronate in Postmenopausal Women With Osteoporosis After a Treatment Period Without Fractures
Alendronate 70mg weekly - Osteoporosis in Post-menopausal Women
Phase 4RecruitingOdense University Hospital14002025-02-212025-03-07
Combined Anabolic Therapy
Romosozumab, Teriparatide - Osteoporosis, Postmenopausal, Osteoporosis
Phase 4RecruitingMassachusetts General Hospital502025-02-032026-10-08
Efficacy of Romosozumab and Denosumab Combined Treatment in Postmenopausal Osteoporosis Patients with Multiple Fragility Fractures
Romosozumab and Denosumab Combination Therapy, Romosozumab Prefilled Syringe [Evenity], Denosumab (Prolia) - Osteoporosis in Post-menopausal Women
Phase 4Not yet recruitingMarmara University602025-01-152024-12-27
Romosozumab Versus Denosumab in Glucocorticoid-induced Osteoporosis: an Extended Observation of a Randomized Controlled Trial at 48 Months
Romosozumab, Denosumab - Osteoporosis, Glucocorticoids Toxicity
Phase 4CompletedTuen Mun Hospital542024-08-202026-05-05
Evaluation of Efficacy and Safety of Prolia in Subjects of Male Osteoporosis in Mainland China
Prolia - Osteoporosis
Phase 4Active not recruitingAmgen1022024-08-062026-02-12
Effects of First-Line Oral Hypoglycemics in Bone Markers of Treatment Naïve Saudi Adults With Type 2 Diabetes
Metformin, Lifestyle - Diabetes Type 2, Osteoporosis
Phase 4UnknownKing Saud University1112024-08-012024-06-03
A Study on the Prevention and Treatment of GIOP With Eldecalcitol
Eldecalcitol capsules, Alfacalcidol tablets, Calcium carbonate tablets - Rheumatoid Arthritis, Osteoporosis
Phase 4UnknownChinese SLE Treatment And Research Group3142024-06-012024-04-25
The Effect of Denosumab on Muscle and Strength and Insulin Sensitivity
Denosumab, Saline (0.9% NaCl) - Osteoporosis
Phase 4RecruitingAarhus University Hospital402024-05-212025-12-15
Preserving Geriatric Muscle With an Osteoporosis Medication
Denosumab 60 MG/ML, Zoledronic Acid 5Mg/Bag 100Ml Infusion - Osteoporosis
Phase 4RecruitingChrissy Kistler1552024-02-082026-09-23

Showing 20 of 220. Sign in to see all of them.

Narrower conditions

Osteoporosis, Postmenopausal (72)  ·  Bone Diseases, Metabolic (37)  ·  Fractures, Bone (14)  ·  Breast Neoplasms (6)  ·  Osteoporotic Fractures (6)  ·  Diabetes Mellitus, Type 2 (4)  ·  Frailty (4)  ·  HIV Infections (4)  ·  Hyperparathyroidism, Primary (4)  ·  Spinal Cord Injuries (4)  ·  Arthritis, Rheumatoid (3)  ·  Cardiovascular Diseases (3)  ·  Cystic Fibrosis (3)  ·  Hypercalcemia (3)

Broader conditions

Metabolic Diseases (220)  ·  Musculoskeletal Diseases (220)  ·  Nutritional and Metabolic Diseases (220)  ·  Bone Diseases (218)  ·  Bone Diseases, Metabolic (183)  ·  Wounds and Injuries (30)  ·  Pathological Conditions, Signs and Symptoms (23)  ·  Immune System Diseases (13)  ·  Skin and Connective Tissue Diseases (13)  ·  Fractures, Bone (12)  ·  Signs and Symptoms (12)  ·  Endocrine System Diseases (11)  ·  Nervous System Diseases (11)  ·  Pathologic Processes (11)

Interventions

Denosumab (34)  ·  Zoledronic Acid (30)  ·  Alendronate (29)  ·  Teriparatide (29)  ·  Risedronic Acid (23)  ·  Ibandronic Acid (22)  ·  Vitamin D (16)  ·  Calcium (14)  ·  romosozumab (14)  ·  Raloxifene Hydrochloride (13)  ·  Cholecalciferol (10)  ·  Calcium Carbonate (5)  ·  Diphosphonates (4)  ·  Estradiol (4)  ·  Kyphoplasty (4)

Sponsors

Eli Lilly and Company (16)  ·  Hoffmann-La Roche (15)  ·  National Taiwan University Hospital (9)  ·  Sanofi (9)  ·  Massachusetts General Hospital (8)  ·  Tuen Mun Hospital (7)  ·  Susan L. Greenspan (5)  ·  University of Aarhus (5)  ·  University of Wisconsin, Madison (5)  ·  Aarhus University Hospital (4)  ·  Amgen (4)  ·  GlaxoSmithKline (4)  ·  Charite University, Berlin, Germany (3)  ·  James J. Peters Veterans Affairs Medical Center (3)  ·  Medical University of Vienna (3)

Countries

United States (82)  ·  Denmark (15)  ·  Canada (14)  ·  China (14)  ·  France (13)  ·  Spain (13)  ·  Germany (11)  ·  South Korea (10)  ·  Taiwan (9)  ·  Greece (8)  ·  Australia (7)  ·  Mexico (7)  ·  United Kingdom (7)  ·  Austria (6)  ·  Belgium (6)

Top investigators

Benjamin Leder, MD (4)  ·  Anne Kenny, MD (3)  ·  Chi Chiu Mok, MD, FRCP (3)  ·  Karen E Hansen, MD (3)  ·  Steven C Kirshblum, M.D. (3)  ·  Susan L Greenspan, MD (3)  ·  Aasis Unnanuntana, MD (2)  ·  Bente L Langdahl, MD PhD DMSc (2)  ·  Bente Langdahl, MD, Professor, DMSc, PhD (2)

Results publications

PMID 34231877, PMID 11138687, PMID 16018754, PMID 33813753, PMID 35478046, PMID 36088628, PMID 38979716, PMID 39527056, PMID 11063900, PMID 1421796, PMID 14742657, PMID 16490909, PMID 17182297, PMID 17355365, PMID 18039992, PMID 18077316, PMID 18539106, PMID 18641106, PMID 18682511, PMID 18838053, PMID 19246088, PMID 19291931, PMID 19474141, PMID 19584192, PMID 19671655, PMID 19929434, PMID 20200964, PMID 20204604, PMID 20578215, PMID 20722847, PMID 20835566, PMID 20863330, PMID 21187295, PMID 21261673, PMID 21289258, PMID 21347742, PMID 21400196, PMID 21703900, PMID 21796066, PMID 21877131, PMID 21912321, PMID 22235252, PMID 22326720, PMID 22350731, PMID 22354743, PMID 22443312, PMID 22848407, PMID 23048011, PMID 23327689, PMID 23446769

NIH funding

2005 (1), 2008 (1), 2015 (1), 2023 (1), 2025 (1), P30AG024827 (1), R01AG018887 (1), R01AG050302 (1), R01AG052123 (1), R01AG059417 (1), R01AG066825 (1), R01AG072797 (1), R01AG074979 (1), R01AR041443 (1), R01AR073191 (1)